# US 2003/0211515 A1 · Novel compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0211515 A1
- Document ID: US20030211515A1
- Status: Published application
- Kind: A1
- Application number: 10/312,162
- Filed: 2002-12-19
- Published: 2003-11-13
- Earliest claimed: 2002-12-19
- Inventors: Amy K Lasek; Henry Yue; Chandra S Arvizu
- Web page: https://patentgrep.com/patent/US20030211515A1

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- A61P 35/00: Antineoplastic agents
- C07K 14/78: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
- G01N 33/5752: of the lungs
- G01N 33/57535: of the large intestine, e.g. colon, rectum or anus
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12Q 2600/158: Expression markers
- G01N 2500/00: Screening for compounds of potential therapeutic value
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Polypeptides and polynucleotides of the genes set forth in Table 1 and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing polypeptides and polynucleotides of the genes set forth in Table 1 in diagnostic assays.

## Claims

### Claim 1

An isolated cDNA comprising a nucleic acid sequence encoding a protein having the amino acid sequence of SEQ ID NO: 1, or the complement of the cDNA.

### Claim 2

An isolated cDNA comprising a nucleic acid sequence selected from:
a) SEQ ID NO:2 or the complement thereof;
b) a fragment of SEQ ID NO:2 selected from SEQ ID NOs:3-13 or the complement thereof; and
c) a variant of SEQ ID NO:2 selected from SEQ ID NOs:14-15 or the complement thereof.

### Claim 3 (depends on 1)

A composition comprising the cDNA of claim 1 and a labeling moiety.

### Claim 4 (depends on 1)

A vector comprising the cDNA of claim 1.

### Claim 5 (depends on 4)

A host cell comprising the vector of claim 4.

### Claim 6 (depends on 5)

A method for using a cDNA to produce a protein, the method comprising:
a) culturing the host cell of claim 5 under conditions for protein expression; and
b) recovering the protein from the host cell culture.

### Claim 7 (depends on 3)

A method for using a cDNA to detect expression of a nucleic acid in a sample comprising:
a) hybridizing the composition of claim 3 to nucleic acids of the sample under conditions to form at least one hybridization complex; and
b) detecting hybridization complex formation, wherein complex formation indicates expression of the cDNA in the sample.

### Claim 8 (depends on 7)

The method of claim 7 further comprising amplifying the nucleic acids of the sample prior to hybridization.

### Claim 9 (depends on 7)

The method of claim 7 wherein the composition is attached to a substrate.

### Claim 10 (depends on 7)

The method of claim 7 wherein complex formation is compared with at least one standard to determine differential expression.

### Claim 11 (depends on 1)

A method of using a cDNA to screen a plurality of molecules or compounds, the method comprising:
a) combining the cDNA of claim 1 with a plurality of molecules or compounds under conditions to allow specific binding; and
b) detecting specific binding, thereby identifying a molecule or compound which specifically binds the cDNA.

### Claim 12 (depends on 11)

The method of claim 11 wherein the molecules or compounds are selected from DNA molecules, RNA molecules, peptide nucleic acids, artificial chromosome constructions, peptides, transcription factors, repressors, and regulatory molecules.

### Claim 13 (depends on 6)

A purified protein or a portion thereof produced by the method of claim 6 and selected from:
a) an amino acid sequence of SEQ ID NO:1;
b) an antigenic epitope of SEQ ID NO: 1; and
c) a biologically active portion of SEQ ID NO:1.

### Claim 14 (depends on 13)

A composition comprising the protein of claim 13 and a pharmaceutical carrier.

### Claim 15 (depends on 13)

A method for using a protein to screen a plurality of molecules or compounds to identify at least one ligand, the method comprising:
a) combining the protein of claim 13 with the molecules or compounds under conditions to allow specific binding; and
b) detecting specific binding, thereby identifying a ligand which specifically binds the protein.

### Claim 16 (depends on 15)

The method of claim 15 wherein the molecules or compounds are selected from DNA molecules, RNA molecules, peptide nucleic acids, peptides, proteins, mimetics, agonists, antagonists, antibodies, immunoglobulins, inhibitors, and drugs.

### Claim 17 (depends on 15)

A method of using a protein to prepare and purify antibodies comprising:
a) immunizing an animal with the protein of claim 15 under conditions to elicit an antibody response;
b) isolating animal antibodies;
c) attaching the protein to a substrate;
d) contacting the substrate with isolated antibodies under conditions to allow specific binding to the protein;
e) dissociating the antibodies from the protein, thereby obtaining purified antibodies.

### Claim 18 (depends on 17)

An antibody produced by the method of claim 17.

### Claim 19 (depends on 18)

A method for using an antibody to diagnose conditions or diseases associated with expression of a protein, the method comprising:
a) combining the antibody of claim 18 with a sample, thereby forming antibody:protein complexes; and
b) comparing complex formation with a standard, wherein the comparison indicates expression of the protein in the sample.

### Claim 20 (depends on 19)

The method of claim 19 wherein expression is diagnostic of a colon or lung cancer.

### Claim 21 (depends on 18)

A pharmaceutical composition comprising the antibody of claim 18 and a pharmaceutical carrier.

### Claim 22 (depends on 21)

A method for treating a cancer comprising administering to a person in need of such treatment an effective amount of the composition of claim 21.

### Claim 23 (depends on 22)

The method of claim 22 wherein the cancer is a colon cancer.

### Claim 24 (depends on 22)

The method of claim 22 wherein the cancer is a lung cancer.
